{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:32:18Z","timestamp":1769319138013,"version":"3.49.0"},"reference-count":132,"publisher":"National Institute for Health and Care Research","issue":"29","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000276","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["12\/62\/01"],"award-info":[{"award-number":["12\/62\/01"]}],"id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title><jats:p>Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI) and unstable angina (UA). One treatment for ACS is percutaneous coronary intervention (PCI) plus adjunctive treatment with antiplatelet drugs. Dual therapy antiplatelet treatment [aspirin plus either prasugrel (Efient<jats:sup>\u00ae<\/jats:sup>, Daiichi Sankyo Company Ltd UK\/Eli Lilly and Company Ltd), clopidogrel or ticagrelor (Brilique<jats:sup>\u00ae<\/jats:sup>, AstraZeneca)] is standard in UK clinical practice. Prasugrel is the focus of this review.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title><jats:p>The remit is to appraise the clinical effectiveness and cost-effectiveness of prasugrel within its licensed indication for the treatment of ACS with PCI and is a review of National Institute for Health and Care Excellence technology appraisal TA182.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-3\"><jats:title>Data sources<\/jats:title><jats:p>Four electronic databases (MEDLINE, EMBASE, The Cochrane Library, PubMed) were searched from database inception to June 2013 for randomised controlled trials (RCTs) and to August 2013 for economic evaluations comparing prasugrel with clopidogrel or ticagrelor in ACS patients undergoing PCI.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-4\"><jats:title>Methods<\/jats:title><jats:p>Clinical outcomes included non-fatal and fatal cardiovascular (CV) events, adverse effects of treatment and health-related quality of life (HRQoL). Cost-effectiveness outcomes included incremental cost per life-year gained and incremental cost per quality-adjusted life-year (QALY) gained. An independent economic model assessed four mutually exclusive subgroups: ACS patients treated with PCI for STEMI and with and without diabetes mellitus and ACS patients treated with PCI for UA or NSTEMI and with and without diabetes mellitus.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-5\"><jats:title>Results<\/jats:title><jats:p>No new RCTs were identified beyond that reported in TA182. TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel Thrombolysis in Myocardial Infarction 38) compared prasugrel with clopidogrel in ACS patients scheduled for PCI. No relevant economic evaluations were identified. Our analyses focused on a key subgroup of patients: those aged &lt;\u200975 years who weighed &gt;\u200960\u2009kg (no previous stroke or transient ischaemic attack). For the primary composite end point (death from CV causes, non-fatal myocardial infarction or non-fatal stroke) statistically significantly fewer events occurred in the prasugrel arm (8.3%) than in the clopidogrel arm (11%). No statistically significant difference in major bleeding events was noted. However, there was a significant difference in favour of clopidogrel when major and minor bleeding events were combined (3.0 vs. 3.9%). No conclusions could be drawn regarding HRQoL. The results of sensitivity analyses confirmed that it is likely that, for all four ACS subgroups, within 5\u201310 years prasugrel is a cost-effective treatment option compared with clopidogrel at a willingness-to-pay threshold of \u00a320,000 to \u00a330,000 per QALY gained. At the full 40-year time horizon, all estimates are &lt;\u2009\u00a310,000 per QALY gained.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-6\"><jats:title>Limitations<\/jats:title><jats:p>Lack of data precluded a clinical comparison of prasugrel with ticagrelor; the comparative effectiveness of prasugrel compared with ticagrelor therefore remains unknown. The long-term modelling exercise is vulnerable to major assumptions about the continuation of early health outcome gains.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-7\"><jats:title>Conclusion<\/jats:title><jats:p>A key strength of the review is that it demonstrates the cost-effectiveness of prasugrel compared with clopidogrel using the generic price of clopidogrel. Although the report demonstrates the cost-effectiveness of prasugrel compared with clopidogrel at a threshold of \u00a320,000 to \u00a330,000 per QALY gained, the long-term modelling is vulnerable to major assumptions regarding long-term gains. Lack of data precluded a clinical comparison of prasugrel with ticagrelor; the comparative effectiveness of prasugrel compared with ticagrelor therefore remains unknown. Well-audited data are needed from a long-term UK clinical registry on defined ACS patient groups treated with PCI who receive prasugrel, ticagrelor and clopidogrel.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-8\"><jats:title>Study registration<\/jats:title><jats:p>This study is registered as PROSPERO CRD42013005047.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-9\"><jats:title>Funding<\/jats:title><jats:p>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta19290","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T07:39:52Z","timestamp":1429774792000},"page":"1-130","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Prasugrel (Efient\u00ae) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis"],"prefix":"10.3310","volume":"19","author":[{"given":"Janette","family":"Greenhalgh","sequence":"first","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Bagust","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Boland","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Dwan","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Fleeman","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"McEntee","sequence":"additional","affiliation":[{"name":"North West Medicines Information Centre, Pharmacy Practice Unit, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yenal","family":"Dundar","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marty","family":"Richardson","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fisher","sequence":"additional","affiliation":[{"name":"The Institute for Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2015,4]]},"reference":[{"key":"key20150421124025477_ref1-bib1","unstructured":"Egton Medical Information Systems Ltd. Acute Coronary Syndromes. 2013. URL: www.patient.co.uk\/doctor\/acute-coronary-syndrome (accessed April 2013)."},{"key":"key20150421124025477_ref1-bib2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.hrtlng.2009.10.013","article-title":"Physiological and anatomical bases for sex differences in pain and nausea as presenting symptoms of acute coronary syndromes","volume":"39","author":"Arslanian-Engoren","year":"2010","journal-title":"Heart Lung"},{"key":"key20150421124025477_ref1-bib3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/hrt.2007.138537","article-title":"Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events","volume":"95","author":"Dey","year":"2009","journal-title":"Heart"},{"key":"key20150421124025477_ref1-bib4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.amjcard.2008.11.034","article-title":"Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus","volume":"103","author":"Hasin","year":"2009","journal-title":"Am J Cardiol"},{"key":"key20150421124025477_ref1-bib5","unstructured":"MINAP. How the NHS Cares for Patients with Heart Attack. Annual Public Report April 2012\u2013March 2013. 2013. URL: www.hqip.org.uk\/assets\/NCAPOP-Library\/NCAPOP-2013-14\/MINAP-Audit-Report-2013-LOW.pdf (accessed November 2013)."},{"issue":"31","key":"key20150421124025477_ref1-bib6","doi-asserted-by":"publisher","DOI":"10.3310\/hta15310","article-title":"Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis","volume":"15","author":"Greenhalgh","year":"2011","journal-title":"Health Technol Assess"},{"key":"key20150421124025477_ref1-bib7","unstructured":"NICE. Prasugrel with Percutaneous Coronary Intervention for Treating Acute Coronary Syndrome (Review of TA182): Final Scope. 2013. URL: http:\/\/guidance.nice.org.uk\/TA\/WaveR\/141 (accessed 2013 October)."},{"key":"key20150421124025477_ref1-bib8","unstructured":"NICE. Myocardial infarction with ST-segment-elevation (STEMI): The Acute Management of Myocardial Infarction with ST-segment-elevation (STEMI): NICE Clinical Guideline CG167. 2013 URL: http:\/\/publications.nice.org.uk\/myocardial-infarction-with-st-segment-elevation-cg167 (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib9","unstructured":"National Institute for Cardiovascular Outcomes Research. National Audit of Percutaneous Coronary Interventional Procedures Public Report 2011. London: National Institute for Cardiovascular Outcomes Research (NICOR). 2011. URL: www.ucl.ac.uk\/nicor\/audits\/adultcardiacintervention\/publicreports\/documents\/pcireport2012 (accessed April 2013)."},{"key":"key20150421124025477_ref1-bib10","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib11","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib12","unstructured":"Egton Medical Information Systems Ltd. Percutaneous Coronary Intervention. 2013. URL: www.patient.co.uk\/doctor\/percutaneous-coronary-intervention (accessed April 2013)."},{"key":"key20150421124025477_ref1-bib13","unstructured":"NICE. The Early Management of Unstable Angina and Non-ST-segment-Elevation Myocardial Infarction: NICE Clinical Guideline 94. 2010. URL: www.nice.org.uk\/guidance\/cg94\/evidence\/cg94-unstable-angina-and-nstemi-full-guidance-and-appendices2 (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib14","unstructured":"Global Registry of Acute Coronary Events. GRACE ACS Risk Model. 2013. URL: www.outcomes-umassmed.org\/grace\/acs_risk\/acs_risk_content.html (accessed May 2013)."},{"key":"key20150421124025477_ref1-bib15","doi-asserted-by":"publisher","DOI":"10.3310\/hta14Suppl1\/05","article-title":"Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention","volume":"14","author":"Greenhalgh","year":"2010","journal-title":"Health Technol Assess"},{"key":"key20150421124025477_ref1-bib16","unstructured":"Health and Social Care Information Centre. Hospital Episode Statistics: Admitted Patient Care 2012\u201313. Diagnosis. 2012\u201313 URL: www.hscic.gov.uk\/catalogue\/PUB12566\/hosp-epis-stat-admi-summ-rep-2012-13-rep.pdf (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib17","unstructured":"British Cardiovascular Intervention Society. BCIS Audit Returns \u2013 Adult Interventional Procedures. 2012. URL: www.bcis.org.uk\/pages\/page_box_contents.asp?pageid=780&navcatid=11 (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib18","unstructured":"NICE. NICE Quality Standards: QS forward planner. 2013. URL: www.nice.org.uk\/guidance\/qualitystandards\/qualitystandards.jsp?domedia=1&mid=6D55F322-CBF6-F672\u201300B5C83632967E35 (accessed December 2013)."},{"key":"key20150421124025477_ref1-bib19","unstructured":"NICE quality standards [QS68]. Acute Coronary Syndromes (Including Myocardial Infarction). URL: www.nice.org.uk\/guidance\/qs68 (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib20","unstructured":"NICE. NICE Pathways: Acute Coronary Syndrome Overview. 2013. URL: http:\/\/pathways.nice.org.uk\/pathways\/acute-coronary-syndrome (accessed December 2013)."},{"key":"key20150421124025477_ref1-bib21","unstructured":"NICE. Prasugrel for the Treatment of Acute Coronary Syndromes with Percutaneous Coronary Intervention: TA182. 2009. URL: http:\/\/publications.nice.org.uk\/prasugrel-for-the-treatment-of-acute-coronary-syndromes-with-percutaneous-coronary-intervention-ta182 (accessed October 2013)."},{"key":"key20150421124025477_ref1-bib22","unstructured":"NICE. Ticagrelor for the Treatment of Acute Coronary Syndromes (ACS): TA236. 2011. URL: http:\/\/publications.nice.org.uk\/ticagrelor-for-the-treatment-of-acute-coronary-syndromes-ta236 (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib23","unstructured":"NICE. MI \u2013 Secondary Prevention. Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction: NICE Clinical Guideline CG172. 2013. URL: http:\/\/publications.nice.org.uk\/mi-secondary-prevention-cg172 (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib24","unstructured":"Electronic Medicines Compendium. Efient \u2013 SPC. 2014; URL: www.medicines.org.uk\/emc\/medicine\/21504 (accessed February 2014)."},{"key":"key20150421124025477_ref1-bib25","unstructured":"EMEA. European Public Assessment Report for Efient. 2009. URL: www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Efient\/H-984-en6.pdf (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib26","unstructured":"NICE. Acute Coronary Syndrome \u2013 Prasugrel. Appendix A: Decision Paper Presented to the Institute\u2019s Guidance Executive. 2012. URL: http:\/\/guidance.nice.org.uk\/TA182\/ReviewDecisionJune12\/ReviewDecisionAppendix\/pdf\/English (accessed 2013 October)."},{"key":"key20150421124025477_ref1-bib27","volume-title":"British National Formulary","author":""},{"key":"key20150421124025477_ref1-bib28","unstructured":"NHS Prescription Services. Electronic Drug Tariff 2013. URL: www.ppa.org.uk\/edt\/November_2013\/mindex.htm (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib29","unstructured":"Electronic Medicines Compendium. Clopidogrel \u2013 SPC. 2013. URL: www.medicines.org.uk\/emc\/medicine\/24206\/SPC\/Plavix+300mg+tablets\/#CONTRAINDICATIONS (accessed October 2013)"},{"key":"key20150421124025477_ref1-bib30","unstructured":"European Medicines Agency. Brilique. 2013. URL: www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001241\/human_med_001398.jsp&mid=WC0b01ac058001d124 (accessed December 2013)."},{"key":"key20150421124025477_ref1-bib31","unstructured":"Electronic Medicines Compendium. Brilique \u2013 SPC. 2013. URL: www.medicines.org.uk\/emc\/medicine\/23935\/SPC\/Brilique+90+mg+film+coated+tablets\/ (accessed October 2013)."},{"key":"key20150421124025477_ref1-bib32","unstructured":"AstraZeneca PLC. Third Quarter and Nine Months Results (2013). 2013. URL: www.astrazeneca.com\/cs\/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DPress-release.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285660598284&ssbinary=true (accessed November 2013)."},{"key":"key20150421124025477_ref1-bib33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"key20150421124025477_ref1-bib34","author":"","year":"2013","journal-title":"EU Watchdogs Demand Info on AstraZeneca\u2019s Disputed Brilinta Trial"},{"key":"key20150421124025477_ref1-bib35","volume-title":"CRD\u2019s Guidance for Undertaking Reviews in Healthcare: Systematic Reviews","author":"","year":"2009","edition":"3rd edn."},{"key":"key20150421124025477_ref1-bib36","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"key20150421124025477_ref1-bib37","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1185\/03007995.2010.502048","article-title":"Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial","volume":"26","author":"Ge","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"key20150421124025477_ref1-bib38","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Investigators J-T. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circulation Cardiovasc Interv"},{"key":"key20150421124025477_ref1-bib40","first-page":"41","article-title":"Ticagrelor vs prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"33","author":"Xanthopoulou","year":"2012","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","article-title":"Investigators T-T. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am Heart J"},{"key":"key20150421124025477_ref1-bib42","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.amjcard.2011.05.020","article-title":"Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies","volume":"108","author":"Wiviott","year":"2011","journal-title":"Am J Cardiol"},{"key":"key20150421124025477_ref1-bib43","unstructured":"SIGN. Acute Coronary Syndromes. 2007. URL: www.sign.ac.uk\/pdf\/sign93.pdf (accessed October 2013)."},{"key":"key20150421124025477_ref1-bib44","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib45","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"key20150421124025477_ref1-bib46","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"key20150421124025477_ref1-bib47","doi-asserted-by":"crossref","first-page":"A209","DOI":"10.1016\/S1098-3015(10)70664-1","article-title":"International comparison of health care resources and quality of life in acute coronary syndrome patients in 2007: results from the AntiPlatelet Treatment Observational Registry (APTOR)","volume":"11","author":"Bakhai","year":"2008","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib48","doi-asserted-by":"crossref","unstructured":"McCollam P, Bae J, Nasuti P, Anger C. Clopidogrel Patterns of Use in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention in 5 European Countries. PCV107. Poster presented at the International Society of Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, 2008.","DOI":"10.1016\/S1098-3015(10)66405-4"},{"key":"key20150421124025477_ref1-bib49","unstructured":"McCollam P, Bae J, Nasuti P, Yeung E, Hamad B. Clopidogrel Patterns of Use in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention in 5 European Countries. P01294. Presentation presented at the European Society of Cardiology Congress, Vienna, 2007."},{"key":"key20150421124025477_ref1-bib50","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.amjcard.2007.05.048","article-title":"Meta-Analysis Appraising High Clopidogrel Loading in Patients Underqoinq Percutaneous Coronary Intervention(dagger)","volume":"100","author":"Lotrionte","year":"2007","journal-title":"Am J Cardiol"},{"key":"key20150421124025477_ref1-bib51","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/S0735-1097(01)01702-8","article-title":"American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes","volume":"38","author":"Cannon","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"key20150421124025477_ref1-bib52","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1161\/CIRCULATIONAHA.108.833665","article-title":"Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib53","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/eurheartj\/ehm355","article-title":"Universal definition of myocardial infarction","volume":"28","author":"Thygesen","year":"2007","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1161\/CIRCULATIONAHA.111.041160","article-title":"American College of Cardiology\/American Heart Association\/European Society of Cardiology\/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)","volume":"125","author":"Bonaca","year":"2012","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"key20150421124025477_ref1-bib56","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"key20150421124025477_ref1-bib57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijcard.2010.08.035","article-title":"Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes","volume":"150","author":"Biondi-Zoccai","year":"2011","journal-title":"Int J Cardiol"},{"key":"key20150421124025477_ref1-bib58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11239-012-0838-z","article-title":"Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis","volume":"36","author":"Chatterjee","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"key20150421124025477_ref1-bib59","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ijcard.2011.05.083","article-title":"Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis","volume":"150","author":"Passaro","year":"2011","journal-title":"Int J Cardiol"},{"key":"key20150421124025477_ref1-bib60","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1160\/TH11-08-0586","article-title":"Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions","volume":"108","author":"Steiner","year":"2012","journal-title":"Thromb Haemost"},{"key":"key20150421124025477_ref1-bib61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"key20150421124025477_ref1-bib62","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijcard.2011.06.036","article-title":"Agreement between adjusted indirect comparison and simplified network meta-analyses on prasugrel and ticagrelor","volume":"151","author":"Biondi-Zoccai","year":"2011","journal-title":"Int J Cardiol"},{"key":"key20150421124025477_ref1-bib63","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","article-title":"Investigators D-. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key20150421124025477_ref1-bib64","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in unstable angina to prevent recurrent events trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"key20150421124025477_ref1-bib65","first-page":"793","article-title":"A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation","volume":"122","author":"Han","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"key20150421124025477_ref1-bib66","first-page":"971","article-title":"Doubling the maintenance dose of clopidogrel in patients with high post-clopidogrel platelet reactivity after percutaneous coronary intervention: the DOSER randomized placebo-controlled trial","volume":"31","author":"Aradi","year":"2010","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib67","unstructured":"Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N, et al. Prasugrel With Percutaneous Coronary Intervention for Treating Acute Coronary Syndromes (Review of TA182). 2013. URL: www.nice.org.uk\/nicemedia\/live\/13908\/64290\/64290.pdf (accessed 2013 December)."},{"key":"key20150421124025477_ref1-bib68","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1997","edition":"2nd edn."},{"key":"key20150421124025477_ref1-bib69","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.109.900704","article-title":"Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocadial infarction TRITON-TIMI 38","volume":"121","author":"Mahoney","year":"2010","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib70","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1161\/CIRCULATIONAHA.110.936757","article-title":"Letter by Serebruany regarding article \u2018Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction TRITON-TIMI 38\u2019","volume":"122","author":"Serebruany","year":"2010","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib71","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIRCULATIONAHA.110.951889","article-title":"Response to letter regarding article \u2018Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction TRITON-TIMI 38\u2019","volume":"122","author":"Mahoney","year":"2010","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib72","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3111\/13696998.2013.768998","article-title":"Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands and Turkey","volume":"16","author":"Davies","year":"2013","journal-title":"J Med Econ"},{"key":"key20150421124025477_ref1-bib73","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3111\/13696998.2011.637590","article-title":"Cost-effectiveness of prasugrel in a US managed care population","volume":"15","author":"Mauskopft","year":"2011","journal-title":"J Med Econ"},{"key":"key20150421124025477_ref1-bib74","doi-asserted-by":"publisher","first-page":"A329","DOI":"10.1016\/S1098-3015(10)74616-7","article-title":"Prasugrel cost-effective relative to clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention from the perspective of the UK national health service? A model-based analysis","volume":"12","author":"Davies","year":"2009","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib75","doi-asserted-by":"publisher","first-page":"A331","DOI":"10.1016\/S1098-3015(10)74628-3","article-title":"Is prasugrel cost-effective relative to clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention from the perspective of the German health care system? A model-based analysis","volume":"12","author":"Davies","year":"2009","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib76","doi-asserted-by":"publisher","first-page":"A357","DOI":"10.1016\/S1098-3015(11)72428-7","article-title":"Prasugrel vs. clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a Spanish model-based cost-effectiveness analysis","volume":"13","author":"Davies","year":"2010","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib77","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/hrt.2010.202853","article-title":"Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE technology appraisal guidance","volume":"96","author":"Hill","year":"2010","journal-title":"Heart"},{"key":"key20150421124025477_ref1-bib78","first-page":"146","article-title":"Cost-effectiveness of prasugrel and clopidogrel for acute coronary syndrome in a medicaid population","volume":"16","author":"Keast","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"key20150421124025477_ref1-bib79","doi-asserted-by":"publisher","first-page":"A328","DOI":"10.1016\/S1098-3015(10)74614-3","article-title":"Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned PCI: Results from the triton-timi 38 trial from the German perspective","volume":"12","author":"Mahoney","year":"2009","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib80","doi-asserted-by":"publisher","first-page":"A535","DOI":"10.1016\/j.jval.2011.08.1515","article-title":"Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the private sector in Mexico","volume":"14","author":"Mondragon","year":"2011","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib81","doi-asserted-by":"publisher","first-page":"A545","DOI":"10.1016\/j.jval.2011.08.1579","article-title":"Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the public health care system in Mexico","volume":"14","author":"Mondragon","year":"2011","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib82","doi-asserted-by":"publisher","first-page":"A39","DOI":"10.1016\/j.jval.2011.02.229","article-title":"A decision modeling approach to evaluate the cost-effectiveness of prasugrel versus clopidogrel in patients with planned percutaneous coronary intervention","volume":"14","author":"Rao","year":"2011","journal-title":"Value Health"},{"key":"key20150421124025477_ref1-bib83","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2796.1998.00394.x","article-title":"Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16 year follow up of the Primary Prevention Study, Goteberg, Sweden","volume":"244","author":"Rosengren","year":"1998","journal-title":"J Intern Med"},{"key":"key20150421124025477_ref1-bib84","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ahj.2005.05.019","article-title":"Comparison of long-term mortality across the spectrum of acute coronary syndromes","volume":"151","author":"Allen","year":"2006","journal-title":"Am Heart J"},{"key":"key20150421124025477_ref1-bib85","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/0735-1097(95)00270-1","article-title":"Prognostic significance of nonfatal reinfarction during 3-year follow up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators","volume":"26","author":"Mueller","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"key20150421124025477_ref1-bib86","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ehj.2004.08.009","article-title":"Mortality following non-ST elevation acute coronary syndrome: 4 years follow up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK)","volume":"25","author":"Taneja","year":"2004","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib87","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan","year":"2006","journal-title":"Med Decis Making"},{"key":"key20150421124025477_ref1-bib88","unstructured":"MIMS. Prescription Drug Database: MIMS. 2013. URL: www.mims.co.uk\/ (accessed November 2014)."},{"key":"key20150421124025477_ref1-bib89","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1001\/jama.293.23.2908","article-title":"Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials","volume":"293","author":"Mehta","year":"2005","journal-title":"J Am Med Assoc"},{"key":"key20150421124025477_ref1-bib90","volume-title":"Guide to the Methods of Technology Appraisal","author":"","year":"2013"},{"key":"key20150421124025477_ref1-bib91","volume-title":"UK Population Norms for EQ-5D","author":"Kind","year":"1999"},{"key":"key20150421124025477_ref1-bib92","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"","year":"1996","journal-title":"Lancet"},{"key":"key20150421124025477_ref1-bib93","volume-title":"Prasugrel for the Treatment of Acute Coronary Syndromes with Percutaneous Coronary Intervention: A Single Technology Appraisal","author":"Greenhalgh","year":"2009"},{"key":"key20150421124025477_ref1-bib94","unstructured":"NICE. Clopidogrel and Modified-Release Dypiridamole in the Prevention of Occlusive Vascular Events: TA90 (replaced by TA210). 2005. URL: www.nice.org.uk\/TA090 (accessed December 2013)."},{"key":"key20150421124025477_ref1-bib95","unstructured":"NICE. Vascular Disease \u2013 Clopidogrel and Dipyridamole (TA210). 2010. URL: http:\/\/guidance.nice.org.uk\/TA210 (accessed December 2013)."},{"key":"key20150421124025477_ref1-bib96","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","article-title":"Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study","volume":"7","author":"Diener","year":"2008","journal-title":"Lancet Neurol"},{"key":"key20150421124025477_ref1-bib97","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/01.CIR.102.9.1014","article-title":"Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction","volume":"102","author":"Malmberg","year":"2000","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib98","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/oxfordjournals.aje.a114979","article-title":"Mortality among diabetics in a national sample","volume":"128","author":"Kleinman","year":"1988","journal-title":"Am J Epidemiol"},{"key":"key20150421124025477_ref1-bib99","unstructured":"Curtis L. Unit Costs of Health and Social Care 2012 (PSSRU). 2012. URL: www.pssru.ac.uk\/project-pages\/unit-costs\/2012\/ (accessed November 2014)."},{"key":"key20150421124025477_ref1-bib100","unstructured":"AstraZeneca. Ticagrelor for the Treatment of Acute Coronary Syndromes: Manufacturer Submission. 2010. URL: www.nice.org.uk\/nicemedia\/live\/12169\/55171\/55171.pdf (accessed November 2014)."},{"key":"key20150421124025477_ref1-bib101","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0272989X09349961","article-title":"Mapping the modified Rankin Scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome","volume":"30","author":"Arias","year":"2010","journal-title":"Med Decis Making"},{"key":"key20150421124025477_ref1-bib102","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Med Decis Making"},{"key":"key20150421124025477_ref1-bib103","unstructured":"ClinicalTrials.gov. Prospective, Randomised Trial of Ticagrelor Versus Prasugrel in Patients with Acute Coronary Syndrome (ISAR-REACT 5). 2013. URL: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01944800?term=ticagrelor&rank=41 (accessed November 2014)."},{"key":"key20150421124025477_ref1-bib104","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12265-013-9527-3","article-title":"Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy\u2014Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial","volume":"7","author":"Schulz","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"key":"key20150421124025477_ref1-bib105","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","article-title":"Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis","volume":"51","author":"Antman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key20150421124025477_ref1-bib106","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.110.002683","article-title":"Predictors of bleeding and time dependence of association of bleeding with mortality: Insights from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 (TRITON-TIMI 38)","volume":"123","author":"Hochholzer","year":"2011","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib107","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.amjcard.2012.10.035","article-title":"Safety and efficacy of prasugrel use in patients undergoing percutaneous coronary intervention and anticoagulated with bivalirudin","volume":"111","author":"Laynez","year":"2013","journal-title":"Am J Cardiol"},{"key":"key20150421124025477_ref1-bib108","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"New Engl J Med"},{"key":"key20150421124025477_ref1-bib109","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"key20150421124025477_ref1-bib110","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib111","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1093\/eurheartj\/ehn362","article-title":"Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial","volume":"29","author":"Murphy","year":"2008","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib112","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jacc.2009.05.025","article-title":"The efficacy and safety of prasugrel with and without a glycoprotein IIb\/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis","volume":"54","author":"O\u2019Donoghue","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key20150421124025477_ref1-bib113","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"key20150421124025477_ref1-bib114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.06.021","article-title":"Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy","volume":"158","author":"Pride","year":"2009","journal-title":"Am Heart J"},{"key":"key20150421124025477_ref1-bib115","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jcin.2010.05.012","article-title":"Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy","volume":"3","author":"Pride","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"key20150421124025477_ref1-bib116","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0091270011406280","article-title":"Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy","volume":"52","author":"Riesmeyer","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"key20150421124025477_ref1-bib117","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ijcard.2010.10.040","article-title":"Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world","volume":"155","author":"Ruff","year":"2012","journal-title":"Int J Cardiol"},{"key":"key20150421124025477_ref1-bib118","doi-asserted-by":"publisher","first-page":"E340","DOI":"10.1016\/S0735-1097(12)60341-6","article-title":"Timing and clinical setting of cardiovascular death or myocardial infarction following PCI for ACS-observations from the TRITON-TIMI 38 trial","volume":"1","author":"Scirica","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key20150421124025477_ref1-bib119","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key20150421124025477_ref1-bib120","doi-asserted-by":"publisher","first-page":"A9309","DOI":"10.1016\/j.jcin.2014.01.160","article-title":"Benefit of prasugrel in ST-elevation myocardial infarction according to timing of percutaneous coronary intervention: Insight from the triton-TIMI 38 study","volume":"124","author":"Udell","year":"2011","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib121","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"key20150421124025477_ref1-bib122","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","article-title":"Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial","volume":"371","author":"Wiviott","year":"2008","journal-title":"Lancet"},{"key":"key20150421124025477_ref1-bib123","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1177\/0091270009337942","article-title":"Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38","volume":"49","author":"Wrishko","year":"2009","journal-title":"J Clin Phamacol"},{"key":"key20150421124025477_ref1-bib124","volume-title":"The Clinical and Cost-Effectiveness of Prasugrel with Percutaneous Coronary Intervention for Treating Acute Coronary Syndromes (Review of TA182)","author":"Greenhalgh","year":"2013"},{"key":"key20150421124025477_ref1-bib125","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.amjcard.2008.03.073","article-title":"Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents","volume":"102","author":"Abuzahra","year":"2008","journal-title":"Am J Cardiol"},{"key":"key20150421124025477_ref1-bib126","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1160\/TH07-09-0562","article-title":"Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study","volume":"99","author":"Angiolillo","year":"2008","journal-title":"Thromb Haemost"},{"key":"key20150421124025477_ref1-bib127","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.thromres.2009.06.016","article-title":"A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg\/day versus 75 mg\/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study","volume":"125","author":"Palmerini","year":"2010","journal-title":"Thromb Res"},{"key":"key20150421124025477_ref1-bib128","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"key20150421124025477_ref1-bib129","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jcin.2008.09.004","article-title":"Clopidogrel 150 mg\/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study","volume":"1","author":"Aleil","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"key20150421124025477_ref1-bib130","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","article-title":"A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75\u2009mg of clopidogrel for 30 days","volume":"28","author":"von Beckerath","year":"2007","journal-title":"Eur Heart J"},{"key":"key20150421124025477_ref1-bib131","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ahj.2011.07.026","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150\u2009mg) clopidogrel","volume":"162","author":"Alexopoulos","year":"2011","journal-title":"Am Heart J"},{"key":"key20150421124025477_ref1-bib132","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","article-title":"Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19290\/hta19290.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19290\/hta19290.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:35:20Z","timestamp":1692113720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta19290\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":132,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2015,4]]}},"alternative-id":["10.3310\/hta19290"],"URL":"https:\/\/doi.org\/10.3310\/hta19290","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}